Search research articles
Contact Us
Filters
Showing results (81-90 of 118) with videos related to
Page
of 12
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 8, 2020
FDA Approval Summary: Lurbinectedin for the Treatment of Metastatic Small Cell Lung Cancer
Sonia Singh, Adnan A Jaigirdar, Flora Mulkey, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 4, 2024
FDA Approval Summary: Enfortumab Vedotin plus Pembrolizumab for Locally Advanced or Metastatic Urothelial Carcinoma
Michael H Brave, William F Maguire, Chana Weinstock, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 14, 2018
FDA Approval: Ribociclib for the Treatment of Postmenopausal Women with Hormone Receptor-Positive, HER2-Negative Advanced or Metastatic Breast Cancer
Anand Shah, Erik Bloomquist, Shenghui Tang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 27, 2013
First FDA approval of dual anti-HER2 regimen: pertuzumab in combination with trastuzumab and docetaxel for HER2-positive metastatic breast cancer
Gideon M Blumenthal, Nancy S Scher, Patricia Cortazar, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 10, 2020
FDA Approval Summary: Accelerated Approval of Sacituzumab Govitecan-hziy for Third-line Treatment of Metastatic Triple-negative Breast Cancer
Sakar Wahby, Lola Fashoyin-Aje, Christy L Osgood, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 11, 2018
U.S. Food and Drug Administration Approval: Neratinib for the Extended Adjuvant Treatment of Early-Stage HER2-Positive Breast Cancer
Harpreet Singh, Amanda J Walker, Laleh Amiri-Kordestani, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 19, 2015
FDA Approval Summary: Olaparib Monotherapy in Patients with Deleterious Germline BRCA-Mutated Advanced Ovarian Cancer Treated with Three or More Lines of Chemotherapy
Geoffrey Kim, Gwynn Ison, Amy E McKee, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 23, 2021
FDA Approval Summary: Fam-Trastuzumab Deruxtecan-Nxki for the Treatment of Unresectable or Metastatic HER2-Positive Breast Cancer
Preeti Narayan, Christy L Osgood, Harpreet Singh, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 29, 2021
U.S. FDA Drug Approvals for Breast Cancer: A Decade in Review
Shaily Arora, Preeti Narayan, Christy L Osgood, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 15, 2020
FDA Approval Summary: Tucatinib for the Treatment of Patients with Advanced or Metastatic HER2-positive Breast Cancer
Mirat Shah, Suparna Wedam, Joyce Cheng, et al.
Page
of 12
Search research articles
Search
Showing results (81-90 of 118) with videos related to
Sort By:
Page
of 12
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 8, 2020
FDA Approval Summary: Lurbinectedin for the Treatment of Metastatic Small Cell Lung Cancer
Sonia Singh, Adnan A Jaigirdar, Flora Mulkey, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 4, 2024
FDA Approval Summary: Enfortumab Vedotin plus Pembrolizumab for Locally Advanced or Metastatic Urothelial Carcinoma
Michael H Brave, William F Maguire, Chana Weinstock, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 14, 2018
FDA Approval: Ribociclib for the Treatment of Postmenopausal Women with Hormone Receptor-Positive, HER2-Negative Advanced or Metastatic Breast Cancer
Anand Shah, Erik Bloomquist, Shenghui Tang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 27, 2013
First FDA approval of dual anti-HER2 regimen: pertuzumab in combination with trastuzumab and docetaxel for HER2-positive metastatic breast cancer
Gideon M Blumenthal, Nancy S Scher, Patricia Cortazar, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 10, 2020
FDA Approval Summary: Accelerated Approval of Sacituzumab Govitecan-hziy for Third-line Treatment of Metastatic Triple-negative Breast Cancer
Sakar Wahby, Lola Fashoyin-Aje, Christy L Osgood, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 11, 2018
U.S. Food and Drug Administration Approval: Neratinib for the Extended Adjuvant Treatment of Early-Stage HER2-Positive Breast Cancer
Harpreet Singh, Amanda J Walker, Laleh Amiri-Kordestani, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 19, 2015
FDA Approval Summary: Olaparib Monotherapy in Patients with Deleterious Germline BRCA-Mutated Advanced Ovarian Cancer Treated with Three or More Lines of Chemotherapy
Geoffrey Kim, Gwynn Ison, Amy E McKee, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 23, 2021
FDA Approval Summary: Fam-Trastuzumab Deruxtecan-Nxki for the Treatment of Unresectable or Metastatic HER2-Positive Breast Cancer
Preeti Narayan, Christy L Osgood, Harpreet Singh, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 29, 2021
U.S. FDA Drug Approvals for Breast Cancer: A Decade in Review
Shaily Arora, Preeti Narayan, Christy L Osgood, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 15, 2020
FDA Approval Summary: Tucatinib for the Treatment of Patients with Advanced or Metastatic HER2-positive Breast Cancer
Mirat Shah, Suparna Wedam, Joyce Cheng, et al.
Page
of 12